[Estimation of an NY-ESO-1 expressing HCC cell line by NY-ESO-1b specific CD8+T cells in vitro induced by HLA-A2 restricted NY-ESO-1b peptide].
To analyze the effect of an NY-ESO-1 expressing HCC cell line by NY-ESO-1b specific CD8(+)T cells in vitro induced by HLA-A2 Restricted NY-ESO-1b peptide and to further analyze the possibility of NYjESOj1 as a vaccine in HCC treatment. Peripheral blood mononuclear cells (PBMCs) were obtained from an HLA-A2(+) HCC patient and NY-ESO-1 specific CD8(+)T cells were in vitro induced by HLA-A2 Restricted NY-ESO-1b peptide. Next we estimated the effect that NY-ESO-1 specific CD8(+)T cells recognized and killed NY-ESO-1 expressing HepG2 cells by enzyme-linked immunospot(ELISPOT). These in vitro induced NY-ESO-1b specific CD8(+)T cells could recognize HepG2 cells stably transfected with NY-ESO-1 in both IFN-gamma and Granzyme B ELISPOT assays. And the data also showed that NY-ESO-1 specific CD8(+)T cells could efficiently kill NY-ESO-1 expressing HepG2 cells. NY-ESO-1 protein can be processed by HCC cells, and that HLA-A2 restricted NY-ESO-1b peptide (157-165) can also be presented on the surfaces of cells and recognized by NY-ESO-1b specific CD8(+)T cells in vitro induced.